![Seeking Alpha](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/665/normal/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336)
Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
Seeking Alpha,
Follow Summary Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance.